Clinical Relevance of the Effects of Plasma Expanders on Coagulation

 

 Buy Article Permissions and Reprints

ABSTRACT

Patients with severe bleeding are often treated with colloids as plasma replacement fluids, including dextrans, gelatin-based solutions, or starches. Many of these agents will affect the hemostatic system beyond their effect on hemodilution. Obviously, the ensuing impairment of coagulation is not desirable in patients with major blood loss. However, there is considerable controversy whether the anticoagulant effects of the various compounds will truly translate into clinically relevant effects, such as increased blood loss or, even more importantly, transfusion requirements, the need for surgical (re) exploration, organ dysfunction, or mortality. In this overview, we discuss the effects of various plasma replacement solutions on the coagulation system and review the controlled clinical studies with different plasma expanders on clinically significant end points. We conclude that most plasma expanders have indeed marked effects at various points in the hemostatic system and that there are significant differences between various plasma replacement fluids but that clinically relevant effects on bleeding are mostly present if large volumes (i.e., > 1.5 L) are infused or if the patient has a concomitant or preexistent hemostatic impairment.

REFERENCES

• 1 de Jonge E, Levi M. Effects of different plasma substitutes on blood coagulation: a comparative review.  Crit Care Med. 2001;  29 1261-1267
  CrossrefPubMedGoogle Scholar
• 2 Marik P E, Iglesias J. Would the colloid detractors please sit down!.  Crit Care Med. 2000;  28 2652-2654
  PubMedGoogle Scholar
• 3 Choi P T, Yip G, Quinonez L G, Cook D J. Crystalloids vs. colloids in fluid resuscitation: a systematic review.  Crit Care Med. 1999;  27 200-210
  CrossrefPubMedGoogle Scholar
• 4 Treib J, Baron J F, Grauer M T, Strauss R G. An international view of hydroxyethyl starches.  Intensive Care Med. 1999;  25 258-268
  PubMedGoogle Scholar
• 5 Salmon J B, Mythen M G. Pharmacology and physiology of colloids.  Blood Rev. 1993;  7 114-120
  CrossrefPubMedGoogle Scholar
• 6 Lundsgaard-Hansen P, Tschirren B. Clinical experience with 120,000 units of modified fluid gelatin.  Dev Biol Stand. 1980;  48 251-256
  PubMedGoogle Scholar
• 7 Mardel S N, Saunders F M, Allen H et al.. Reduced quality of clot formation with gelatin-based plasma substitutes.  Br J Anaesth. 1998;  80 204-207
  CrossrefPubMedGoogle Scholar
• 8 Ruttmann T G, James M F, Viljoen J F. Haemodilution induces a hypercoagulable state.  Br J Anaesth. 1996;  76 412-414
  PubMedGoogle Scholar
• 9 Tabuchi N, de Haan J, Gallandat Huet R C, Boonstra P W, van Oeveren W. Gelatin use impairs platelet adhesion during cardiac surgery.  Thromb Haemost. 1995;  74 1447-1451
  PubMedGoogle Scholar
• 10 de Jonge E, Levi M, Berends F et al.. Impaired haemostasis by intravenous administration of a gelatin-based plasma expander in human subjects.  Thromb Haemost. 1998;  79 286-290
  PubMedGoogle Scholar
• 11 Clagett G P, Anderson Jr F A, Heit J, Levine M, Wheeler H B. Prevention of venous thromboembolism.  Chest. 1995;  108 312S-334S
  CrossrefPubMedGoogle Scholar
• 12 Batlle J, del Rio F, Lopez Fernandez M F, Martin R, Lopez B A. Effect of dextran on factor VIII/von Willebrand factor structure and function.  Thromb Haemost. 1985;  54 697-699
  PubMedGoogle Scholar
• 13 Zhang B, Wieslander J B. Dextran's antithrombotic properties in small arteries are not altered by low-molecular-weight heparin or the fibrinolytic inhibitor tranexamic acid: an experimental study.  Microsurgery. 1993;  14 289-295
  CrossrefPubMedGoogle Scholar
• 14 Bergman A, Andreen M, Blomback M. Plasma substitution with 3% dextran-60 in orthopaedic surgery: influence on plasma colloid osmotic pressure, coagulation parameters, immunoglobulins and other plasma constituents.  Acta Anaesthesiol Scand. 1990;  34 21-29
  PubMedGoogle Scholar
• 15 Lethagen S, Rugarn P, Aberg M, Nilsson I M. Effects of desmopressin acetate (DDAVP) and dextran on hemostatic and thromboprophylactic mechanisms.  Acta Chir Scand. 1990;  156 597-602
  PubMedGoogle Scholar
• 16 Eriksson M, Saldeen T. Effect of dextran on plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) during surgery.  Acta Anaesthesiol Scand. 1995;  39 163-166
  PubMedGoogle Scholar
• 17 Carr M E, Gabriel D A. The effect of dextran 70 on the structure of plasma-derived fibrin gels.  J Lab Clin Med. 1980;  96 985-993
  PubMedGoogle Scholar
• 18 Dalrymple-Hay M, Aitchison R, Collins P, Sekhar M, Colvin B. Hydroxyethyl starch induced acquired von Willebrand's disease.  Clin Lab Haematol. 1992;  14 209-211
  PubMedGoogle Scholar
• 19 Damon L, Adams M, Stricker R B, Ries C. Intracranial bleeding during treatment with hydroxyethyl starch.  N Engl J Med. 1987;  317 964-965
  PubMedGoogle Scholar
• 20 Cope J T, Banks D, Mauney M C et al.. Intraoperative hetastarch infusion impairs hemostasis after cardiac operations.  Ann Thorac Surg. 1997;  63 78-82
  CrossrefPubMedGoogle Scholar
• 21 Stump D C, Strauss R G, Henriksen R A, Petersen R E, Saunders R. Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII.  Transfusion. 1985;  25 349-354
  CrossrefPubMedGoogle Scholar
• 22 Kapiotis S, Quehenberger P, Eichler H G et al.. Effect of hydroxyethyl starch on the activity of blood coagulation and fibrinolysis in healthy volunteers: comparison with albumin.  Crit Care Med. 1994;  22 606-612
  PubMedGoogle Scholar
• 23 Thyes C, Madjdpour C, Frascarolo P et al.. Effect of high- and low-molecular-weight low-substituted hydroxyethyl starch on blood coagulation during acute normovolemic hemodilution in pigs.  Anesthesiology. 2006;  105 1228-1237
  CrossrefPubMedGoogle Scholar
• 24 Tigchelaar I, Gallandat Huet R C, Korsten J, Boonstra P W, van Oeveren W. Hemostatic effects of three colloid plasma substitutes for priming solution in cardiopulmonary bypass.  Eur J Cardiothorac Surg. 1997;  11 626-632
  CrossrefPubMedGoogle Scholar
• 25 Treib J, Haass A, Pindur G et al.. All medium starches are not the same: influence of the degree of hydroxyethyl substitution of hydroxyethyl starch on plasma volume, hemorrheologic conditions, and coagulation.  Transfusion. 1996;  36 450-455
  CrossrefPubMedGoogle Scholar
• 26 de Jonge E, Levi M, Buller R, Berends F, Kesecioglu J. Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects.  Intensive Care Med. 2001;  27 1825-1829
  CrossrefPubMedGoogle Scholar
• 27 Rackow E C, Mecher C, Astiz M E et al.. Effects of pentastarch and albumin infusion on cardiorespiratory function and coagulation in patients with severe sepsis and systemic hypoperfusion.  Crit Care Med. 1989;  17 394-398
  PubMedGoogle Scholar
• 28 Strauss R G, Stump D C, Henriksen R A, Saunders R. Effects of hydroxyethyl starch on fibrinogen, fibrin clot formation, and fibrinolysis.  Transfusion. 1985;  25 230-234
  CrossrefPubMedGoogle Scholar
• 29 Ruttmann T G, James M F, Aronson I. In vivo investigation into the effects of haemodilution with hydroxyethyl starch (200/0.5) and normal saline on coagulation.  Br J Anaesth. 1998;  80 612-616
  CrossrefPubMedGoogle Scholar
• 30 Nielsen V G. High-molecular-weight hydroxyethyl starch accelerates kallikrein-dependent clot initiation.  J Trauma. 2007;  62 1491-1494
  PubMedGoogle Scholar
• 31 Egli G A, Zollinger A, Seifert B et al.. Effect of progressive haemodilution with hydroxyethyl starch, gelatin and albumin on blood coagulation.  Br J Anaesth. 1997;  78 684-689
  PubMedGoogle Scholar
• 32 Gandhi S D, Weiskopf R B, Jungheinrich C et al.. Volume replacement therapy during major orthopedic surgery using Voluven (hydroxyethyl starch 130/0.4) or hetastarch.  Anesthesiology. 2007;  106 1120-1127
  CrossrefPubMedGoogle Scholar
• 33 Boldt J, Muller M, Heesen M, Heyn O, Hempelmann G. Influence of different volume therapies on platelet function in the critically ill.  Intensive Care Med. 1996;  22 1075-1081
  CrossrefPubMedGoogle Scholar
• 34 Brummel-Ziedins K, Whelihan M F, Ziedins E G, Mann K G. The resuscitative fluid you choose may potentiate bleeding.  J Trauma. 2006;  61 1350-1358
  CrossrefPubMedGoogle Scholar
• 35 Hjertberg H, Olsson J, Ekstrom T, Lisander B. Do low molecular weight heparin and dextran increase the blood loss in transurethral resection of the prostate?.  Br J Urol. 1996;  78 897-900
  PubMedGoogle Scholar
• 36 Bergqvist D, Kettunen K, Fredin H et al.. Thromboprophylaxis in patients with hip fractures: a prospective, randomized, comparative study between Org 10172 and dextran 70.  Surgery. 1991;  109 617-622
  PubMedGoogle Scholar
• 37 Lisander B, Jacobsson S A, Ivarsson I, Vegfors M, Engdahl O. Giving both enoxaparin and dextran increases the need for transfusion in revision hip arthroplasty.  Eur J Surg. 1996;  162 861-866
  PubMedGoogle Scholar
• 38 Boldt J, Knothe C, Zickmann B et al.. Influence of different intravascular volume therapies on platelet function in patients undergoing cardiopulmonary bypass.  Anesth Analg. 1993;  76 1185-1190
  PubMedGoogle Scholar
• 39 Niemi T T, Suojaranta-Ylinen R T, Kukkonen S I, Kuitunen A H. Gelatin and hydroxyethyl starch, but not albumin, impair hemostasis after cardiac surgery.  Anesth Analg. 2006;  102 998-1006
  CrossrefPubMedGoogle Scholar
• 40 Boldt J, Scholhorn T, Mayer J, Piper S, Suttner S. The value of an albumin-based intravascular volume replacement strategy in elderly patients undergoing major abdominal surgery.  Anesth Analg. 2006;  103 191-199
  CrossrefPubMedGoogle Scholar
• 41 Mortelmans Y J, Vermaut G, Verbruggen A M et al.. Effects of 6% hydroxyethyl starch and 3% modified fluid gelatin on intravascular volume and coagulation during intraoperative hemodilution.  Anesth Analg. 1995;  81 1235-1242
  PubMedGoogle Scholar
• 42 Arellano R, Gan B S, Salpeter M J et al.. A triple-blinded randomized trial comparing the hemostatic effects of large-dose 10% hydroxyethyl starch 264/0.45 versus 5% albumin during major reconstructive surgery.  Anesth Analg. 2005;  100 1846-1853
  CrossrefPubMedGoogle Scholar

Marcel LeviM.D. 

Department of Internal Medicine, Academic Medical Centre F-4

Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

Email: m.m.levi@amc.uva.nl